Table 1.
Baseline characteristics for patients in the intervention and control group
| Intervention group (n = 25) | Control group (n = 22) | |
|---|---|---|
| Age, years | 58 (± 15) | 58 (± 13) |
| Male sex, n (%) | 12 (80) | 20 (91) |
| BMI, kg/m 2 | 25.9 (± 4.39) | 27.5 (± 5) |
| Potassium supp., n(%) | 3 (12) | 6 (27) |
| MRA treatment, n(%) | 8 (32) | 5 (23) |
| Beta Blocker treatment, n(%) | 18 (72) | 16 (73) |
| ACEi/ARB treatment, n(%) | 17 (68) | 13 (59) |
| Diuretic treatment, n(%) | 9 (36) | 9 (41) |
| IHD, n(%) | 7 (28) | 10 (45) |
| DCM, n(%) | 9 (36) | 7 (32) |
| Afib, n(%) | 2 (8) | 2(9) |
| Diabetes, n(%) | 1 (4) | 2 (9) |
| p-K, mmol/l | 3.92 (± 0.19) | 3.98 (± 0.2) |
| p-Na, mmol/l | 140 (± 2) | 141 (± 3) |
| p-Mg, mmol/l | 0.85 (± 0.051) | 0.85 (± 0.071) |
| p-creatinine, µmol/l) | 88 (± 22.2) | 82.2 (± 14.7) |
| Syst. blood pressure, mmHg | 127 (± 19) | 133 (± 15) |
| Diast. blood pressure, mmHg | 80.4 (± 13) | 81.7 (± 9.8) |
| GLS, % | -14.7 (± 3.12) | -14.5 (± 3.2) |
| MD, ms | 52.2 (± 17) | 60.6 (± 18.4) |
| LVEF, % | 48.7 (± 6.11) | 47.5 (± 7.1) |
| E, cm/s | 61.1 (± 28.3) | 62 (± 24.3) |
| A, cm/s | 52.8 (± 19.7) | 51.2 (± 12.1) |
| E/A | 1.27 (± 0.79) | 1.21 (± 0.52) |
| e’, cm/s | 7.1 (± 2.23) | 7.52 (± 2.42) |
| E/e’ | 9.49 (± 4.81) | 9.01 (± 3.65) |
| TAPSE, cm | 2.18 (± 0.38) | 2.12 (± 0.55) |
| RV FWS, % | -23.6 (± 5.31) | -21.7 (± 4.96) |
Displayed as mean (± SD) or number (%). A: Late diastolic mitral inflow velocity, ACEi: Angiotensin converting enzyme inhibitor, Afib: Atrial fibrillation, ARB: Angiotensin-II receptor blocker, DCM: Dilated cardiomyopathy, E: early diastolic mitral inflow velocity, e’: Early diastolic mitral annular velocity, GLS: Global Longitudinal Strain, IHD: ischemic heart disease, LVEF: Left ventricular ejection fraction, MD: Mechanical dispersion, MRA: Mineralocorticoid receptor antagonist, RV FWS: Right ventricular free wall strain, TAPSE: Tricuspid annular plane systolic excursion